PATH Key Stats
- NuPathe Management Discusses Q3 2013 Results - Earnings Call Transcript Seeking Alpha Nov 14
- NuPathe Announces Third Quarter 2013 Financial Results and Recent Operational Highlights noodls Nov 14
- NUPATHE INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Nov 14
- NuPathe, Inc. (PATH) Posts Q3 Loss of 25c/Share Street Insider Nov 14
- Q3 2013 Nupathe Inc Earnings Release - Before Market Open Nov 14
- NuPathe to Host Conference Call to Discuss Third Quarter 2013 Results on Thursday, November 14, 2013 noodls Nov 11
- NuPathe (PATH), LTS Lohmann Enter Chemical Supply, License Agreement Street Insider Oct 15
- NUPATHE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement Oct 15
- NuPathe Doses Adolescent Migraineurs in Clinical Study of ZECUITY Marketwired Sep 23
- NUPATHE INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligatio Sep 19
PATH Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). NuPathe is down 22.00% over the last year vs S&P 500 Total Return up 28.99%, ARCA biopharma down 14.12%, and ACADIA Pharmaceuticals up 433.5%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Balance Sheet View Statement
Pro Ratings for PATH
Pro Strategies Featuring PATH
Did NuPathe make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
NuPathe Inc., is a biopharmaceutical company develops and commercializes branded therapeutics for diseases of the central nervous system, including neurological and psychiatric disorders.